March 8, 2022, Vol 327, No. 10, Pages 897-1003
Long-Acting Cabotegravir for HIV PreventionIssues of Access, Cost, and Equity
Joshua M. Sharfstein, MD; Amy Killelea, JD; Derek Dangerfield, PhD
JAMA. 2022;327(10):921-922. doi:10.1001/jama.2022.0420
This Viewpoint discusses the recent FDA approval of cabotegravir, the first injectable medication to help prevent HIV infection, and how its effectiveness may be complicated by the cost and complexity of the US health care system.